A phase II study of intra-arterial cisplatin with concurrent radiation and erlotinib for locally advanced head and neck cancer

作者：Rao Krishna^*; Kalapurakal Sini; Cha****ni Pratima; Robinson Kathy; Malone James; Clausen Cathy; Ronen Ohad; Dhiwakar Muthuswamy; Shevlin Bruce; Robbins K Thomas

来源：Cancer Chemotherapy and Pharmacology, 2013, 72(3): 545-552.

DOI：10.1007/s00280-013-2225-7

• Head and neck cancer
• Erlotinib
• Cisplatin
• Radiation

Based on the convenient oral dosing of erlotinib and the promising results of biologic therapy, we undertook a phase II study with 21 patients with locally advanced (T3-4) lesions combining radiation with intra-arterial (IA) cisplatin and oral daily erlotinib for a 7-week therapy.
Treatment for the primary tumor and upper neck was given to a total dose of 70 Gy. Chemotherapy with IA cisplatin (150 mg/m(2)) was given on days 1, 8, 15, and 22 concurrently with radiotherapy. During the 7-week treatment period, patients were given erlotinib 150 mg/day.
Overall survival is 63 %, and the relapse/persistent disease rate stands at 36.8 %. A total of 15.2 % of serious adverse event was considered related to erlotinib.
Our study and several others now demonstrate the feasibility of combining anti-epidermal growth factor receptor (EGFR) therapy with chemoradiation, hint at improved survival outcomes with reduced distant metastatic rates, and suggest that maintenance therapy with anti-EGFR agent may be beneficial.

• 出版日期2013-9